Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision
May 7th 2020David Miklos, MD, discusses alternative options to the investigational CAR T-cell therapy KTE-X19 for patients with relapsed/refractory mantle cell lymphoma, while awaiting a regulatory decision from the FDA.
Read More